Liver cancer prevention trial hopes to stop tumors before they start
NCT ID NCT04172779
First seen Nov 20, 2025 · Last updated Apr 28, 2026 · Updated 23 times
Summary
This study tests whether a low dose of the drug erlotinib can prevent liver cancer in 60 adults with advanced liver fibrosis or cirrhosis. Participants will receive either erlotinib or a placebo for a set period. The main goal is to see if the drug changes a blood test linked to liver cancer risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS, LIVER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.